Introduction
============

Limbal deficiency or loss of corneal stem cells is associated with ocular surface disease, which is otherwise known as limbal stem cell deficiency (LSCD). The management of the ocular surface using cultured corneal epithelial cells on a human amniotic membrane is preferred. The ex vivo expansion of limbus culture requires unknown factors, such as fetal bovine serum (FBS), autologous serum, feeder layers or bovine pituitary extracts (BPE), as growth factors for the growth of corneal epithelial cells. The usage of these substances raises concern about infection with recognized or unknown-agents \[[@r1]\]. Although there have been successful reports that support the proliferation of corneal epithelial cells using autologous human serum \[[@r2]\], which effectively eliminates the risk of xenogenic contamination during transplantation to LSCD patients, there has been no data supporting the use of corneal epithelial cultures in a serum-free medium condition or showing the important signaling pathways involved.

B27 was originally optimized for culture of hippocampal neurons and used for the growth of neurons from embryonic rat striatum, the substantia nigra, the subiculum, the cerebral cortex, the postnatal dentate granule, the cerebellum, and the dentate gyrus in a serum-free condition \[[@r3]\]. B27 contains vitamins like biotin, DL-alpha-tocopherol, and DL-alpha-tocopherol acetate. It also contains catalase, human recombinant insulin, superoxide dismutase proteins, and other components such as corticosterone, D-galactose, ethanolamine hydrochloride, reduced glutathione, linoleic acid, linolenic acid, triiodo-L-thyronine, etc. It has been reported that corneal endothelial precursors proliferate actively in B27-containing medium with no FBS or feeder cells \[[@r4]\]. Yakoo et al. \[[@r1]\] established a culture technique for human corneal epithelial equivalents with B27 as an alternative for FBS and studied the pututative markers for corneal epithelial cells. However, the signaling pathway that helps to replace serum components and maintain stemness in the corneal culture has not yet been reported in the literature.

Therefore, we have tried to avoid serum, feeder layers, and/or bovine pituitary extract (BPE) in the culturing of corneal limbal stem cells. Instead, we used a serum-free medium supplemented with the growth factor B27 and analyzed the genes involved in the signal transduction pathway by RT^2^ qPCR profiler array.

Methods
=======

Grading donor eyes
------------------

Human cadaveric eyeballs were obtained from the C.U. Shah eye bank of the Medical Research Foundation, Sankara Nethralaya, Chennai, India with the consent of the donor or donor family to be used for medical research in accordance with the principles outlined in the Declaration of Helsinki. In this study, we collected limbus tissues from donors (n=12) aged between 67and 82 years. Corneal limbal tissues of 2 mm in length were collected in Dulbecco's Modified Eagle Medium (DMEM; Sigma Chemicals, St. Louis, MO) with antibiotics (Sigma Chemicals) and transported to the cell biology laboratory for further processing. The donor blood samples were screened for human immunodeficiency virus (HIV) type 1 and 2, hepatitis B virus (HBV), hepatitis C virus (HCV), and *Treponema pallidum* infections. Data on age, sex, cause of death, time of death, time of eye donation, and time of biopsy collection were also collected.

Human limbal explant culture
----------------------------

The collected limbal tissue was washed thrice with Hanks balanced salt solution buffer (Sigma Chemicals). After careful removal of excessive sclera and conjunctiva, the tissue was cut into multiple bits using a sharp, sterile Bard-Parker blade (Niraj Industries, Faridabad, India). The tissue bits were placed on a culture plate (BD biosciences, San Jose, CA) using a sterile needle. The plate was incubated at 37 °C and 5% CO~2~ for 5 min for adhesion. The explants were covered with culture medium containing equal volumes of DMEM and F12 (Sigma Chemicals) containing 5 ng/ml of epidermal growth factor (EGF), 5 μg/ml of insulin, 5 μg/ml of transferrin, 5 ng/ml of sodium selenite, 0.5 mg/ml of hydrocortisone, and 1% antibiotic solution (Sigma Chemicals). Ten percent FBS (Sigma Chemicals) was added to five cultures (serum-dependent culture; n=5) and 1% B27 supplement (Sigma Chemicals) was added to the other five cultures (serum-free B27 supplemented culture; n=5). The control samples were cultured without serum and/or any other supplement replacing serum (control culture; n=2). The plates were incubated at 37 °C and 5% CO~2~ with 95% humidity~.~ The medium was changed once every two days and growth was monitored daily with an inverted phase contrast microscope (Nikon, Tokyo, Japan). Confluent cells were harvested for further molecular characterization.

Growth kinetics
---------------

The outgrowth of all the cultures was photographed every second day; images were transferred to a computer and analyzed using quantity G area measurement software \[[@r5]\]. The mean radius of all the cultures was plotted against each day until they reached confluence.

Cell proliferation assay
------------------------

Cell proliferation was assessed by measuring 5-bromo-2-deoxyuridine (Qiagen, Santa Clara, CA) incorporation during DNA synthesis in proliferating cells. The detection of BrdU was performed according to the manufacturer's instruction and chased for 1--21 days. The BrdU labeling indices were assessed by counting the nuclei through a microscope using a 40× objective. The labeling index was expressed as the number of positively labeled nuclei/total number of nuclei×100%.

RNA isolation
-------------

The cultures were trypsinised on the 8th day (limbal stem cells) and the 21st day (differentiated corneal cells) from both serum-dependent and serum-free B27 supplemented cultures. The RNA was isolated using the Rneasy (Qiagen) kit according to the manufacturer's instructions. For RT^2^ qPCR array, the integrity and purity of the RNA were verified using a bioanalyzer chip (Agilent Technologies Genotypic, Bangalore, India).

Reverse transcriptase PCR
-------------------------

The expression of marker genes (Bangalore Genei, Bangalore, India; [Table 1](#t1){ref-type="table"}) specific for limbal stem cells and corneal cells was studied by RT--PCR with the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) as an internal control.

###### Primer sequence and reaction condition for RT--PCR.

  **Gene**      **Primer sequence (3′-5′)**   **Annealing temperature (°C)**   **PCR product size (bp)**
  ------------- ----------------------------- -------------------------------- ---------------------------
  *ABCG2*       FP:AGTTCCATGGCACTGGCCATA      62                               379
                RP:TCAGGTAGGCAATTGTGAAGG                                        
  *ΔNp63*       FP:CAGACTCAATTTAGTGAG         54                               440
                RP:AGCTCATGGTTGGGGCAC                                           
  Connexin 43   FP:CCTTCTTGCTGATCCAGTGGTAC    66                               154
                RP:ACCAAGGACACCACCAGCAT                                         
  Keratin3      FP: GGCAGAGATCGAGGGTGTC       64                               145
                RP: GTCATCCTTCGCCTGCTGTAG                                       
  Keratin12     FP:CATGAAGAAGAACCACGAGGATG    63                               150
                RP:TCTGCTCAGCGATGGTTTCA                                         
  *GAPDH*       FP:GCCAAGGTCATCCATGACAAC      63                               498
                RP:GTCCACCACCCTGTTGCTGTA                                        

**FP**: Forward Primer; **RP**: Reverse Primer; **bp**: Base Pair.

Signal transduction pathway analysis
------------------------------------

The RT^2^ qPCR profiler Human Signal Transduction Pathway array (catalog number PAHS-014; SABiosciences, Frederick, MD), representing 84 genes involved in signal transduction pathways, plus five housekeeping genes and three controls, was used to analyze the effect of serum on signaling-related gene expression in human limbal and corneal epithelial cells. The total RNA was isolated from the limbus and corneal cells (serum-dependent and serum-free B27 supplemented culture) using the Rneasy Mini Kit (Qiagen). cDNA was generated from 1 µg total RNA using the RT^2^ qPCR Array First Strand Kit in accordance with the manual. The template was combined with RT^2^ SYBR Green/Fluorescein PCR master mix. Equal amounts of this mixture (25 μl) were added to each well of the RT^2^ qPCR profiler plate containing the predispensed gene-specific primer sets, and the reaction was performed using a sequence detector (ABI 7500; Applied Biosystems, LabIndia, Chennai, India) according to the manufacturer's protocols. Data analysis was based on the ∆∆C~t~ method with the aid of an Excel (Microsoft Excel; Microsoft, Redmond, WA) spreadsheet containing algorithms provided by the manufacturer. The expression levels of the mRNA of each gene were normalized using the expression of the housekeeping gene *GAPDH*. A positive value indicates that the gene was upregulated and a negative value indicates that the gene was downregulated.

Statistical analysis
--------------------

All experiments were performed in triplicate. The summary data were reported as the mean±standard deviation (SD), and were compiled and analyzed on a computer (Microsoft Excel; Microsoft). The mean and SD were calculated for each group using the Student's *t*-test. Results were considered to be statistically significant when p\<0.01. The results of RT^2^ qPCR are indicated as "fold increase" (mRNA concentrations of serum-free B27 supplemented cultures divided by mRNA concentrations of serum-dependent controls).

Results
=======

Under microscopic observation, we noted epithelial migration from limbal explants at the end of 48 h in both serum-dependent and serum-free B27 supplemented cultures ([Figure 1](#f1){ref-type="fig"}). By the end of the 15th day, 90%--100% confluent growth was seen. There was no growth in the control samples cultured without serum and/or any other supplement.

![Epithelial cell migration from limbal explants. Epithelial cell migration from limbal explants in serum-free B27 supplemented at the end of 48 h (**A**); serum-dependent culture at the end of 48 h (**B**); confluent culture of corneal epithelial cells in serum-free B27 supplemented at the end of the 15th day (**C**); confluent culture of corneal epithelial cells in serum-dependent culture at the end of the 15th day (**D**).](mv-v16-1169-f1){#f1}

Growth kinetics
---------------

The cells cultured in serum-free B27 supplemented medium showed significantly higher growth after 12 days ([Figure 2](#f2){ref-type="fig"}). The growth rate was faster on cells cultured in a serum-free B27 supplemented culture when compared to a serum-dependent medium (p\<0.005).

![Growth kinetics of corneal epithelial cultures plotted with area of growth in mm^2^ (x-axis), against serum-free B27 supplemented and serum-dependent cultures (y-axis).](mv-v16-1169-f2){#f2}

Cell proliferation
------------------

The labeling index was high in serum-free B27 supplemented culture when compared to serum-dependent culture after 24 h. The cultures were reviewed continuously for 7, 14, and 21 days and the labeling indices were 50±7.76, 42±2.24, 20±2.0, and 12±0.2%, respectively, in serum-free B27 supplemented culture. Similarly, in the serum-dependent culture, the labeling indices were 48±3.2, 35±0.33, 17±1.7, and 9±1.1% for 7, 14, and 21 days, respectively ([Figure 3](#f3){ref-type="fig"}).

![Cell proliferation index plotted with BrdU labeling indices (x-axis), against serum-free B27 supplemented and serum-dependent cultures (y-axis).](mv-v16-1169-f3){#f3}

RT--PCR
-------

Semiquantitative RT--PCR results showed similar expressions ([Table 2](#t2){ref-type="table"}) of various markers such as transformation-related protein 63 - *p63*, ATP-binding cassette sub-family G member 2 - *ABCG2*, connexin 43, and Keratin 3/Keratin 12 -- *K3/K12* of differentiated corneal epithelial cells (21st day) grown in the serum-dependent and serum-free B27 supplemented medium ([Figure 4](#f4){ref-type="fig"}).

###### mRNA expression of cultured corneal cells grown in serum-dependent and serum-free B27 supplemented medium.

  **Markers**   **Serum-dependent**   **B27-dependent**
  ------------- --------------------- -------------------
  ABCG2         \-                    \-
  P63           \+                    \+
  Connexin 43   \+                    \+
  Keratin 3     \+                    \+
  Keratin 12    \+                    \+

*GAPDH* is an internal control; + positive marker; - negative marker.

![RT--PCR for mRNA expression of putative limbal/corneal stem cell markers. Lane 1: Negative control; Lane 2: Positive control; Lane 3: serum-free B27 supplemented corneal cells; Lane 4: serum-dependent corneal cells; Lane 5: 100 bp DNA ladder.](mv-v16-1169-f4){#f4}

Comparison of signal transduction pathway genes supporting the expansion of serum-dependent and serum-free B27 supplemented culture
-----------------------------------------------------------------------------------------------------------------------------------

The array experiment was performed in duplicate. A simple comparison was performed on data to assess the gene expression of a serum-free B27 supplemented culture in relation a serum-dependent culture as a control for limbal stem cells and differentiated corneal epithelial cells ([Table 3](#t3){ref-type="table"}). The differences in gene expression between the serum-free B27 supplemented culture and the serum-dependent profile of limbal and corneal cells were studied (a more than twofold difference was considered significant). The raw data, i.e., the mean ∆∆C~t~ values of the genes, were normalized to the housekeeping gene *GAPDH*. All 84 genes were analyzed thoroughly based on their role in both the serum and serum-free conditions. Among these pathways, the most interesting and highly expressed were wnt, hedgehog, survival, NFkB, Jak-Stat, and the calcium protein kinase C pathways that have been discussed in this study ([Figure 5](#f5){ref-type="fig"}).

###### Signal transduction pathway gene profile supporting the expansion of serum-free B27 supplemented limbus/corneal culture (serum-dependent culture as control).

  **Symbol**                                 **Limbus**   **Cornea**   **Description**                                                                         **Gene Name**
  ------------------------------------------ ------------ ------------ --------------------------------------------------------------------------------------- -------------------------
  **Mitogenic Pathway**                                                                                                                                        
  EGR1                                       12.06        1.16         Early growth response 1                                                                 AT225/G0S30
  FOS                                        67.78        1.6          V-fos FBJ murine osteosarcoma viral oncogene homolog                                    AP-1/C-FOS
  JUN                                        8.51         1.64         Jun oncogene                                                                            AP-1/AP1
  **Wnt Pathway**                                                                                                                                              
  CCND1                                      4.28         −1.72        Cyclin D1                                                                               BCL1/D11S287E
  JUN                                        8.51         1.64         Jun oncogene                                                                            AP-1/AP1
  LEF1                                       12.06        1.13         Lymphoid enhancer-binding factor 1                                                      DKFZp586H0919/TCF1ALPHA
  MYC                                        4.28         −3.56        V-myc myelocytomatosis viral oncogene homolog (avian)                                   MRTL/bHLHe39
  PPARG                                      2.14         −1.33        Peroxisome proliferator-activated receptor gamma                                        CIMT1/NR1C3
  TCF7                                       12.06        1.13         Transcription factor 7 (T-cell specific, HMG-box)                                       TCF-1
  VEGFA                                      1.07         −1.74        Vascular endothelial growth factor A                                                    MVCD1/VEGF
  WISP1                                      11.65        1.13         WNT1 inducible signaling pathway protein 1                                              CCN4/WISP1c
  **Hedgehog Pathway**                                                                                                                                         
  BMP2                                       8.52         −3.57        Bone morphogenetic protein 2                                                            BMP2A
  BMP4                                       4.32         −2.46        Bone morphogenetic protein 4                                                            BMP2B/BMP2B1
  EN1                                        11.76        1.13         Engrailed homeobox 1                                                                    Engrailed 1
  FOXA2                                      12.06        1.13         Forkhead box A2                                                                         HNF3B/TCF3B
  PTCH1                                      2.01         −2.46        Patched homolog 1 (Drosophila)                                                          BCNS/HPE7
  WNT1                                       12.06        1.13         Wingless-type MMTV integration site family, member 1                                    INT1
  WNT2                                       12.06        1.17         Wingless-type MMTV integration site family member 2                                     INT1L1/IRP
  **TGF-Beta Pathway**                                                                                                                                         
  CDKN1A                                     3.00         −2.47        Cyclin-dependent kinase inhibitor 1A (p21, Cip1)                                        CAP20/CDKN1
  CDKN1B                                     5.99         1.65         Cyclin-dependent kinase inhibitor 1B (p27, Kip1)                                        CDKN4/KIP1
  CDKN2A                                     −1.34        −6.95        Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)                     ARF/CDK4I
  CDKN2B                                     2.12         −1.75        Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)                               CDK4I/INK4B
  **Survival Pathway**                                                                                                                                         
  **PI3 Kinase/AKT Pathway**                                                                                                                                   
  BCL2                                       12.06        1.13         B-cell CLL/lymphoma 2                                                                   Bcl-2
  CCND1                                      4.28         −1.72        Cyclin D1                                                                               BCL1/D11S287E
  JUN                                        8.51         1.64         Jun oncogene                                                                            AP-1/AP1
  MYC                                        4.28         −3.56        V-myc myelocytomatosis viral oncogene homolog (avian)                                   MRTL/bHLHe39
  **Jak/Src Pathway**                                                                                                                                          
  BCL2                                       12.06        1.13         B-cell CLL/lymphoma 2                                                                   Bcl-2
  BCL2L1                                     6.03         −7.04        BCL2-like 1                                                                             BCL-XL/S
  **NFkB Pathway**                                                                                                                                             
  BCL2A1                                     1.50         2.33         BCL2-related protein A1                                                                 ACC-1/ACC-2
  BIRC2                                      2.13         3.24         Baculoviral IAP repeat-containing 2                                                     API1/HIAP2
  BIRC3                                      1.06         −2.48        Baculoviral IAP repeat-containing 3                                                     AIP1/API2
  NAIP (BIRC1)                               2.13         1.14         NLR family, apoptosis inhibitory protein                                                BIRC1/NLRB1
  TERT                                       12.06        1.13         Telomerase reverse transcriptase                                                        EST2/TCS1
  **P53 Pathway**                                                                                                                                              
  BAX                                        3.01         −14.1        BCL2-associated X protein                                                               BCL2L4
  CDKN1A                                     3.00         −2.47        Cyclin-dependent kinase inhibitor 1A (p21, Cip1)                                        CAP20/CDKN1
  Fas                                        −1.33        −1.25        Fas (TNF receptor superfamily, member 6)                                                ALPS1A/APO-1
  GADD45A                                    5.99         2.26         Growth arrest and DNA-damage-inducible, alpha                                           DDIT1/GADD45
  IGFBP3                                     −14.95       −40          Insulin-like growth factor binding protein 3                                            BP-53/IBP3
  MDM2                                       1.06         −4.93        Mdm2 p53 binding protein homolog (mouse)                                                HDMX/hdm2
  TP5313                                     4.28         −1.22        Tumor protein p53 inducible protein 3                                                   PIG3
  **Stress Pathway**                                                                                                                                           
  ATF2                                       3.01         −2.48        Activating transcription factor 2                                                       CRE-BP1/CREB2
  FOS                                        67.78        1.6          V-fos FBJ murine osteosarcoma viral oncogene homolog                                    AP-1/C-FOS
  HSF1 (tcf5)                                4.25         1.15         Heat shock transcription factor 1                                                       HSTF1
  HSPB1 (hsp27)                              4.27         −1.25        Heat shock 27 kDa protein 1                                                             CMT2F/DKFZp586P1322
  HSPCA (hsp90)                              1.50         −3.48        Heat shock protein 90 kDa alpha (cytosolic), class A member 2                           HSP90ALPHA/HSPCA
  MYC                                        4.28         −3.56        V-myc myelocytomatosis viral oncogene homolog (avian)                                   MRTL/bHLHe39
  TP53                                       1.07         −1.75        Tumor protein p53                                                                       LFS1/TRP53
  **NFkB Pathway**                                                                                                                                             
  IKBKB                                      2.11         −2.53        Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta              IKK-beta/IKK2
  IL1A                                       8.48         3.27         Interleukin 1, alpha                                                                    IL-1A/IL1
  IL2                                        11.72        1.17         Interleukin 2                                                                           IL-2/TCGF
  IL8                                        1.53         −9.92        Interleukin 8                                                                           CXCL8/GCP-1
  LTA (TNF beta)                             11.75        1.13         Lymphotoxin alpha (TNF superfamily, member 1)                                           LT/TNFB
  NOS2A (iNOS)                               1.42         −3.52        Nitric oxide synthase 2, inducible                                                      HEP-NOS/INOS
  PECAM1                                     8.03         1.09         Platelet/endothelial cell adhesion molecule                                             CD31/PECAM-1
  TANK                                       5.70         −3.63        TRAF family member-associated NFKB activator                                            I-TRAF/TRAF2
  TNF                                        7.99         −1.75        Tumor necrosis factor (TNF superfamily, member 2)                                       DIF/TNF-alpha
  VCAM1                                      12.06        1.13         Vascular cell adhesion molecule 1                                                       CD106/DKFZp779 G2333
  **NFAT Pathway**                                                                                                                                             
  CD5                                        11.65        1.13         CD5 molecule                                                                            LEU1/T1
  FASLG (TNFSF6)                             11.69        1.16         Fas ligand (TNF superfamily, member 6)                                                  APT1LG1/CD178
  IL2                                        11.72        1.17         Interleukin 2                                                                           IL-2/TCGF
  **CREB Pathway**                                                                                                                                             
  CYP19A1                                    11.27        1.13         Cytochrome P450, family 19, subfamily A, polypeptide 1                                  ARO/ARO1
  EGR1                                       12.06        1.16         Early growth response 1                                                                 AT225/G0S30
  FOS                                        67.78        1.6          V-fos FBJ murine osteosarcoma viral oncogene homolog                                    AP-1/C-FOS
  **Jak-Stat pathway**                                                                                                                                         
  CXCL9                                      11.14        1.13         Chemokine (C-X-C motif) ligand 9                                                        CMK/Humig
  IL4                                        11.33        1.13         Interleukin 4                                                                           BCGF-1/BCGF1
  IL4R                                       1.51         −3.52        Interleukin 4 receptor                                                                  CD124/IL4RA
  MMP10                                      3.02         −1.76        Matrix metallopeptidase 10 (stromelysin 2)                                              SL-2/STMY2
  NOS2A (iNOS)                               1.42         −3.52        Nitric oxide synthase 2, inducible                                                      HEP-NOS/INOS
  **Estrogen Pathway**                                                                                                                                         
  BCL2                                       12.06        1.13         B-cell CLL/lymphoma 2                                                                   Bcl-2
  BRCA1                                      8.50         1.1          Breast cancer 1, early onset                                                            BRCAI/BRCC1
  GREB1                                      11.72        1.16         GREB1 protein                                                                           KIAA0575
  NRIP1                                      −1.32        −3.51        Nuclear receptor interacting protein 1                                                  RIP140
  **Androgen Pathway**                                                                                                                                         
  CDK2                                       8.55         −1.75        Cyclin-dependent kinase 2                                                               p33(CDK2)
  CDKN1A                                     3.00         −2.47        Cyclin-dependent kinase inhibitor 1A (p21, Cip1)                                        CAP20/CDKN1
  KLK2                                       11.41        1.16         Kallikrein-related peptidase 2                                                          KLK2A2/hK2
  TMEPAI                                     −1.87        −1.74        Prostate transmembrane protein, androgen induced 1                                      STAG1/TMEPAI
  **Calcium and protein kinase C Pathway**                                                                                                                     
  CSF2                                       11.42        −1.84        Colony stimulating factor 2 (granulocyte-macrophage)                                    GMCSF
  FOS                                        67.78        1.6          V-fos FBJ murine osteosarcoma viral oncogene homolog                                    AP-1/C-FOS
  IL2                                        11.72        1.17         Interleukin 2                                                                           IL-2/TCGF
  JUN                                        8.51         1.64         Jun oncogene                                                                            AP-1/AP1
  MYC                                        4.28         −3.56        V-myc myelocytomatosis viral oncogene homolog (avian)                                   MRTL/bHLHe39
  ODC1                                       8.54         1.65         Ornithine decarboxylase 1                                                               ODC
  PRKCA                                      5.62         1.13         Protein kinase C, alpha                                                                 AAG6/PKC-alpha
  PRKCE                                      2.92         −2.48        Protein kinase C, epsilon                                                               PKCE/nPKC-epsilon
  TFRC                                       −1.30        −1.74        Transferrin receptor (p90, CD71)                                                        CD71/TFR
  **Phospholipase C Pathway**                                                                                                                                  
  BCL2                                       12.06        1.13         B-cell CLL/lymphoma 2                                                                   Bcl-2
  EGR1                                       12.06        1.16         Early growth response 1                                                                 AT225/G0S30
  FOS                                        67.78        1.6          V-fos FBJ murine osteosarcoma viral oncogene homolog                                    AP-1/C-FOS
  ICAM1                                      −2.68        −20.07       Intercellular adhesion molecule 1                                                       BB2/CD54
  JUN                                        8.51         1.64         Jun oncogene                                                                            AP-1/AP1
  NOS2A                                      1.42         −3.52        Nitric oxide synthase 2, inducible                                                      HEP-NOS/INOS
  PTGS2                                      23.98        4.57         Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)   COX-2/COX2
  VCAM1                                      12.06        1.13         Vascular cell adhesion molecule 1                                                       CD106/DKFZp779G2333
  **Insulin Pathway**                                                                                                                                          
  CEBPB                                      2.90         3.3          CCAAT/enhancer binding protein (C/EBP), beta                                            C/EBP-beta
  FASN                                       4.26         1.14         Fatty acid synthase                                                                     FAS/OA-519
  GYS1                                       3.03         3.29         Glycogen synthase 1 (muscle)                                                            GSY/GYS
  HK2                                        2.99         1.69         Hexokinase 2                                                                            DKFZp686M1669/HKII
  LEP                                        12.06        1.13         Leptin                                                                                  OB/OBS
  **LDL Pathway**                                                                                                                                              
  CCL2                                       8.79         1.13         Chemokine (C-C motif) ligand 2                                                          GDCF-2/HC11
  CSF2                                       11.42        −1.84        Colony stimulating factor 2 (granulocyte-macrophage)                                    GMCSF
  SELE                                       11.70        1.13         Selectin E                                                                              CD62E/ELAM
  SELPLG                                     12.06        1.13         Selectin P ligand                                                                       CD162/CLA
  VCAM1                                      12.06        1.13         Vascular cell adhesion molecule 1                                                       CD106/DKFZp779 G2333
  **Retinoic acid Pathway**                                                                                                                                    
  EN1                                        11.76        1.13         Engrailed homeobox1                                                                     Engrailed 1
  HOXA1                                      12.06        1.13         Homeobox A1                                                                             BSAS/HOX1
  RBP1 (CRBP1)                               1.06         −1.74        Retinol binding protein 1, cellular                                                     CRABP-I/CRBP

![Six Pathways with relatively high expressions representing corresponding genes by RT^2^ qPCR profiler array of serum-free B27 supplemented limbus and corneal epithelial cells. Serum-dependent cultured limbus and corneal epithelial cells are the respective controls.](mv-v16-1169-f5){#f5}

Discussion
==========

We have demonstrated the use of serum-free B27 supplemented medium for the growth of corneal epithelial cells. This serum-free medium supported the proliferation and viability of the cells. The cells expressed presumed limbal stem cell association markers and the cornea phenotype, suggesting that the serum-free B27 supplemented medium retained the stemness of cultured cells. The confluent culture was collected and RNA was isolated to analyze the signaling pathway genes involved in both serum-dependent and serum-free B27 supplemented cultures.

The signal transduction pathway genes involved in the growth of corneal epithelial cells help to determine their role in both serum-dependent and serum-free B27 supplemented corneal epithelial cultures. Among the 17 pathways, six pathways involved in the serum-free B27 supplemented culture were discussed, along with their roles in serum-free limbal stem cell and differentiated corneal epithelial cell cultures.

In the serum-free condition of the corneal epithelial cells, the activation of wnt pathway plays a vital role by activating genes like *Homo sapiens* jun oncogene (*JUN*), which codes for a transcription factor called activator protein-1 (AP1) and helps in the differentiation, proliferation, and apoptosis of epithelial cells \[[@r6]\]. Corneal epithelial stem cell proliferation depends on the upregulation of paired box gene 6 (*pax6*) and downregulation of beta-catenin and lymphoid enhancer-binding factor 1 (*Lef-1*) \[[@r7]\]. The hedgehog pathway genes were 2 to 8 times upregulated in serum-free B27 supplemented limbal stem cells when compared with differentiated corneal epithelial cells of the same culture. Sonic hedgehog (Shh) is secreted by stem cells, inducing bone morphogenetic protein 4 (BMP4), and is involved in the self-renewal and development of the epithelium \[[@r8]\]. The wingless-type MMTV integration site family, member 1 (*wnt1*) and Wingless-type MMTV integration site family, member 21 (*wnt2*) genes of this pathway were found to play an equal role (12 times upregulated in relation to the serum-dependent culture) in the maintenance of stemness in limbal epithelial cells of the serum-free B27 supplemented culture. The cellular survival pathway consists of phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene homolog 1 (*PI3K/Akt*), Janus kinase/sarcoma proto oncogene (*Jak/Src*), and nuclear factor kappa-light-chain-enhancer of activated B (*NFkB*) as three major groups of genes. The cyclin D1 (*CCND1*) gene is required for cell cycle G~1~/S transition \[[@r9]\]. Baculoviral Inhibitor of Apoptosis repeat proteins (Birc1) proteins contain BIR domains that can directly bind to active caspases and help in protein--protein interaction \[[@r10]\]. In the stem cell and progenitor cell compartments, the telomerase reverse transcriptase (*TERT*) gene prevents the adverse consequences of dysfunctional telomeres on cell viability and chromosomal stability \[[@r11]\], and enhances the cell cycle entry of quiescent epidermal stem cells \[[@r12]\]. The NFkB pathway genes in serum-free B27 supplemented cells had a distinct fold increase when compared with the control, and a few genes like interleukin 1 alpha (*IL1A*), interleukin 2 (*IL2*), lymphotoxin alpha (*LTA*), platelet/endothelial cell adhesion molecule 1 (*PECAM1*), and vascular cell adhesion molecule 1 (*VCAM1*) exhibited upfolded expression in both limbus and corneal cells. The inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (*IKBKB*) gene produced an enzyme, IKK2 - inhibitor of nuclear factor kappa-B kinase subunit and activated a transcription factor called NFkB. Interleukin genes like *IL1A*, interleukin 8 (*IL8*), and tumor necrosis factor alpha (*TNFα*) present in the NFkB pathway encode for cytokines and chemokines involved in inflammatory processes \[[@r13],[@r14]\]. They also help in the migration of progenitor and pluripotent stem cells \[[@r15]\]. The chemokine (C-X-C motif) ligand 9 (*CXCL9*) and interleukin 4 (*IL4*) genes of the Jak-Stat pathway played an important role in the development and organization of cells, which were upregulated by 12 times in serum-free B27 supplemented limbus culture \[[@r16]\]. Among the other five pathways, the calcium and protein kinase C pathway genes were highly expressed in serum free-B27 supplemented culture when compared to serum-dependent culture. The *Homo sapiens* V-fos FBJ murine osteosarcoma viral oncogene homolog (*FOS*) gene of the calcium and protein kinase C pathway belonged to the transcription factor family \[[@r17]\], which is highly upregulated in serum-free B27 supplemented limbal stem cell cultures.

In conclusion, the B27 supplement activated more signaling pathway genes, helping to provide a higher cell number, good capacity for proliferation, better quality, and more functional pieces of engineered corneal equivalents without the support of serum, a feeder layer, and/or BPE.
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